You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):全球首創JAK/ROCK抑制劑"羅伐昔替尼(ROVADICITINIB)"IB/IIA期臨牀研究結果發表於《血液》
格隆匯 03-10 18:21

格隆匯3月10日丨中國生物製藥(01177.HK)公告,集團自主研發的國家1類創新藥"羅伐昔替尼(Rovadicitinib)"用於治療慢性移植物抗宿主病(cGVHD)的Ib/IIa期臨牀研究結果已發表於國際血液學領域頂級期刊《血液》(Blood,IF:21.0)。

羅伐昔替尼是全球首個兼具JAK和ROCK雙重抑制機制的口服小分子抑制劑,靶向JAK1/2和ROCK1/2,具有抗炎和抗纖維化的雙重作用。該藥物在治療cGVHD、骨髓纖維化、噬血細胞綜合症等疾病中均展現出治療潛力。

JAK和ROCK是調控免疫反應和纖維化進程的兩大關鍵信號通路。羅伐昔替尼通過全球首創的雙重抑制作用,同步阻斷異常免疫激活和纖維化進程,在cGVHD患者中表現出優異的疾病控制率,爲患者提供安全有效的治療選擇。此次研究獲《血液》權威認證,不僅印證了藥物的科學價值,更爲cGVHD患者提供了全新的治療選擇。

集團已於2024年7月向中國國家藥品監督管理局藥品審評中心(CDE)遞交羅伐昔替尼用於治療中高危骨髓纖維化的上市申請,並於2024年10月啓動羅伐昔替尼用於治療中重度cGVHD的III期臨牀試驗。

此外,集團已於2025年1月獲美國食品藥品監督管理局(FDA)批準在美國開展羅伐昔替尼用於治療cGVHD的II期臨牀試驗。集團將加速羅伐昔替尼的全球臨牀開發,推動該產品儘快上市,填補臨牀空白,造福廣大患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account